◎ Sugi Atlas

Atlas / Disease / REM sleep behavior disorder

REM sleep behavior disorder

disease
On this page

Summary

REM sleep behavior disorder (MONDO:0005937) is a disease with 8 GWAS associations across 3 studies and 70 clinical trials. Top therapeutic interventions include terazosin, clonazepam, and oxybate. A subtype of sleep-wake disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

  • GWAS associations: 8
  • Clinical trials: 70

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical nameREM sleep behavior disorder
Mondo IDMONDO:0005937
EFOEFO:0007462
MeSHD020187
DOIDDOID:9091
ICD-10-CMG47.52
SNOMED CT415238003
UMLSC0751772
MedGen199730
Is cancer (heuristic)no

Data availability: 8 GWAS associations (3 studies).

Disease family

This is a subtype of sleep-wake disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by developmental or physiological process › sleep disorder › sleep-wake disorder › REM sleep behavior disorder

Related subtypes (11): bruxism, recurrent hypersomnia, sleep apnea syndrome, hypersomnia, periodic limb movement disorder, autosomal dominant cerebellar ataxia, deafness and narcolepsy, hereditary sensory neuropathy-deafness-dementia syndrome, autoimmune encephalopathy with parasomnia and obstructive sleep apnea, narcolepsy, circadian rhythm sleep disorder, sleep disorder, initiating and maintaining sleep

Subtypes (1): rapid eye movement sleep disorder

Genetics & variants

GWAS landscape

8 GWAS associations across 3 studies. Top hits map to 5 distinct genes (as reported by GWAS).

Top associations by p-value

rsIDp-valueGeneRisk alleleOdds ratio
rs37560593e-16SNCAA1.26
rs100052332e-15SNCAT1.21
rs127521335e-14GBA1T2.09
rs767637152e-10GBA1C2.84
rs50195382e-10SNCAG0.85
rs343118664e-09TMEM175C1.22
rs1178967355e-09INPP5FA1.8
rs76970732e-08SCARB2T1.18

Top studies (by case count)

StudyLead authorYearCasesControlsTitle
GCST90269977Sosero YL20255,40313,020Genome-wide association study of REM sleep behavior disorder in Parkinson’s disease.
GCST90244078Krohn L20222,843139,636Genome-wide association study of REM sleep behavior disorder identifies polygenic risk and brain expression effects.
GCST90204200Krohn L20221,0618,386Genome-wide association study of REM sleep behavior disorder identifies polygenic risk and brain expression effects.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

TierVariants
Tier 1: coding2
Tier 2: splice/UTR1
Tier 3: regulatory0
Tier 4: intronic/intergenic5

MAF distribution

BucketVariants
common (>=0.05)5
low_freq (0.01-0.05)2
rare (<0.01)1
unknown0

Functional consequences

ConsequenceCount
intron_variant5
missense_variant2
3_prime_UTR_variant1

Top variants

rsIDChrPosAllelesMAFConsequenceGenep-valueTier
rs3756059489836121G>A,C0.5intron_variantSNCA3e-16Tier 4: intronic/intergenic
rs10005233489822180C>G,T0.053_prime_UTR_variantSNCA2e-15Tier 2: splice/UTR
rs127521331155235587C>T0.01intron_variantGBA15e-14Tier 4: intronic/intergenic
rs767637151155235843T>C,G0.004missense_variantGBA12e-10Tier 1: coding
rs5019538489715479G>A0.05intron_variantSNCA2e-10Tier 4: intronic/intergenic
rs343118664958159T>C0.19missense_variantTMEM1754e-09Tier 1: coding
rs11789673510119776815G>A0.02intron_variantINPP5F5e-09Tier 4: intronic/intergenic
rs7697073476211481C>G,T0.34intron_variantSCARB22e-08Tier 4: intronic/intergenic

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated or in trials for this disease

No drug has an approved disease-direct ChEMBL indication for this disease.

1 drug in clinical trials for this disease (phase 2–3, investigational): efficacy not established — a trial record, not an indication.

DrugHighest phase
ClonazepamPhase 2

Clinical trials & evidence

Clinical trials

Clinical trials: 70.

Phase distribution (across all retrieved trials)

PhaseTrials
Not specified50
PHASE211
PHASE45
PHASE2/PHASE32
PHASE1/PHASE21
PHASE11

Top trials by phase / activity

NCTPhaseStatusTitle
NCT01453127PHASE4ENROLLING_BY_INVITATIONDaTSCAN Imaging in Aging and Neurodegenerative Disease
NCT05514106PHASE4ENROLLING_BY_INVITATIONMIBG in Aging and Neurologic Disorders
NCT01401413PHASE4COMPLETEDStudy to Determine Whether Ramelteon Helps People With REM Sleep Behavior Disorder
NCT02836743PHASE4UNKNOWNEffect of Slow-release Melatonin (Circadin®) Therapy on Idiopathic RBD: a Pilot Study
NCT04006925PHASE4COMPLETEDTreatment of REM Sleep Behavior Disorder (RBD) With Sodium Oxybate
NCT04152655PHASE2/PHASE3WITHDRAWNA Study of Efficacy and Safety of Idebenone Vs. Placebo in Prodromal Parkinson Disease
NCT05611372PHASE2/PHASE3WITHDRAWNEfficacy and Safety of Rasagiline in Prodromal Parkinson’s Disease
NCT03775096PHASE2ACTIVE_NOT_RECRUITINGAdrenergic Blockers for Cardiac Changes in Early Parkinson’s Disease (Protocol 53136)
NCT04218968PHASE2ACTIVE_NOT_RECRUITINGCardiac Changes in Early Parkinson’s Disease: A Follow up Study
NCT04386317PHASE2ACTIVE_NOT_RECRUITINGTerazosin Effect on Cardiac Changes in Early Parkinson’s Disease
NCT05109364PHASE2ACTIVE_NOT_RECRUITINGTerazosin and Parkinson’s Disease Extension Study
NCT05904717PHASE2ACTIVE_NOT_RECRUITINGEffect of PXS-4728A on Microglia Activation in Participants With Isolated Rapid Eye Movement Sleep Behaviour Disorder
NCT06996652PHASE2NOT_YET_RECRUITINGAn Exploratory Study of the Potential for Rational Immune System Manipulation to Prevent Emergence of Synucleinopathy Manifestations in Persons With REM Sleep Behavior Disorder (RBD)
NCT07443293PHASE2RECRUITINGIMPACT 360 for Parkinson’s Disease
NCT02312908PHASE2COMPLETEDEffect of Clonazepam on REM Sleep Behavior Disorder in Patients With Parkinsonism
NCT02708186PHASE2COMPLETEDStudy Evaluating Nelotanserin for Treatment of REM Sleep Behavior Disorder in Subjects With Dementia (DLB or PDD)
NCT02789592PHASE2UNKNOWNEfficacy and Safety of Melatonin PR and Clonazepam in Patients With REM Sleep Behavior Disorder in Parkinson Disease
NCT02871427PHASE2TERMINATEDOpen-label Study of Nelotanserin in Lewy Body Dementia With Visual Hallucinations or REM Sleep Behavior Disorder
NCT03675282PHASE1/PHASE2COMPLETEDQuantitative Mapping of Substantia Nigra Iron in Parkinson’s Disease (Stages I-IV, REM Sleep Behavior Disorder) and Controls
NCT06644573PHASE1NOT_YET_RECRUITINGEvaluating the Efficacy and Safety of PROSOMNIA Sleep Therapy™ in Patients With Sleep Deprivation and Chronic Insomnia
NCT01799915Not specifiedRECRUITINGNatural History Study of Synucleinopathies
NCT03623672Not specifiedENROLLING_BY_INVITATIONNorth American Prodromal Synucleinopathy Consortium
NCT05205291Not specifiedRECRUITINGMolecular Imaging of Inflammation in Parkinson’s Disease Using LPS and TSPO-PET/MR
NCT05262543Not specifiedRECRUITINGPREdictive Risk Factors of Conversion Into Idiopathic RBD. Italian Study
NCT05471960Not specifiedRECRUITINGNeuroplasticity in RBD
NCT05721911Not specifiedRECRUITINGImplementing a National Biobank of PD With WGS and Functional Assessment of Polygenic Inheritance by iPSC Technology
NCT05757206Not specifiedACTIVE_NOT_RECRUITINGThe Syn-Sleep Study
NCT05826457Not specifiedENROLLING_BY_INVITATIONNorth American Prodromal Synucleinopathy Consortium Stage 2
NCT06193252Not specifiedRECRUITINGSlow-SPEED-NL: Slowing Parkinson’s Early Through Exercise Dosage-Netherlands
NCT06270290Not specifiedRECRUITINGThe COSP-RBD Study: Concussions and Contact Sports in RBD vs Controls
NCT06329453Not specifiedRECRUITINGIntestinal Immunity in Neurologic Disease
NCT06441864Not specifiedRECRUITINGBehavioral Treatment for Nightmares in REM Sleep Behavior Disorder
NCT06467461Not specifiedRECRUITINGIdentification of Prodromal Neurodegeneration in Serotonergic-Induced REM Sleep Behavior Disorder
NCT06582121Not specifiedRECRUITINGStudy of Sleep Disorders in Prodromal and Definite Parkinsons Disease
NCT06629207Not specifiedRECRUITINGArtificial Intelligence in Molecular Imaging: Predicting Parkinson’s Risk in REM Sleep Behavior Disorder
NCT06745011Not specifiedENROLLING_BY_INVITATIONProdromal Model of Parkinson’s Disease Confined to The Peripheral Nervous System
NCT06797284Not specifiedRECRUITINGThe Impact of Light, Electrical, and Magnetic Neuroregulation Interventions on Sleep-wake Disorders
NCT07355842Not specifiedRECRUITINGRole of Slow Waves in the Progression of Neurodegeneration in Isolated REM Sleep Behavior Disorder
NCT07361315Not specifiedRECRUITINGDevelopment and Online Evaluation of an Online Course for Parasomnias
NCT07365566Not specifiedRECRUITINGPain Assessment in Patients With Idiopathic Rapid Eye Movement (REM) Sleep Behaviour Disorder

Drugs tested across these trials (top 30)

MoleculeMax phaseTrials referencing
TERAZOSIN46
CLONAZEPAM43
OXYBATE43
MELATONIN42
CARVEDILOL41
IDEBENONE41
IOFLUPANE41
RAMELTEON41
RASAGILINE41
NELOTANSERIN22
IOBENGUANE I 12311
(R)-Carvedilol02

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.4
BioBTree
v2.0.2

Sources 21

This page pulls from 21 datasets indexed by BioBTree:

chembl_moleculecivic_evidenceclinical_trialsclinvardbsnpdoidefogenccgwasgwas_studyhgncicd10cmmedgenmeshmimmondomondochildmondoparentorphanetsctidumls